Glenmark开始抗病毒药物Favipiravir的3期试验，以检查其对印度COVID-19患者的疗效
Glenmark Pharmaceuticals周二表示
该公司已启动抗病毒药物Favipiravir的3期临床试验，以检查其对印度COVID-19患者的疗效。
孟买公司
上个月已获得印度药品总局（DCGI）的批准，可进行Favipiravir抗病毒片剂治疗COVID-19患者的临床试验。
Glenmark Pharmaceuticals
is the first company in the country to initiate Phase 3 clinical trials on Favipiravir for COVID-19 patients in India, it said in a statement.
Glenmark begins Phase 3 trials of antiviral drug Favipiravir to check efficacy on COVID-19 patients in India
Favipiravir is a generic version of Japan-based Fujifilm Toyama Chemical’s Avigan. Image credit: Reuters
Clinical trials
have commenced and over ten leading government and private hospitals are being enrolled for the study, it added.
Glenmark estimates study completion by July-August 2020, it said.
As per the approved clinical trial protocol,
150 subjects with mild to moderate COVID-19 symptoms will be randomised in the study in a 1:1 ratio to Favipiravir with standard supportive care or standalone standard supportive care.
Treatment duration is a maximum of 14 days and the total study duration will be a maximum of 28 days from randomisation.
Several health and medical experts, both in and outside of Glenmark are eager to see the effect that Favipiravir has on COVID-19 cases.
We believe the study results will be significant as there is currently no effective treatment for the virus,” Glenmark Pharmaceuticals Vice President & Head Clinical Development, Global Specialty/Branded Portfolio Monika Tandon said.
The data we get from these trials will point us in a clearer direction with regard to COVID-19 treatment and management, she added.
Firstpost